PARP1 and neoplasm: Inhibition of PARP, using olaparib or veliparib, partially reversed the resistance caused by cisplatin and 5-FU treatment, and the combination of PARP inhibitors and cisplatin and 5-FU significantly sensitized the tumor response (105).